Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.160 -0.010 (-0.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Lexaria Bioscience’s (NASDAQ: LEXX) 24th Patent Sets Stage for Market Opportunities in Australia
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Optimistic About Upcoming Hypertension Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
Via Investor Brand Network
Lexaria’s (NASDAQ: LEXX) IP Portfolio Grows Following Receipt of 24th Granted Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience (NASDAQ: LEXX) Commences DehydraTECH-CBD Epilepsy Research Program
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of DehydraTECH-CBD Epilepsy Research Program
Via Investor Brand Network
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
- Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; - DehydraTECH-CBD test articles have been delivered to the laboratory ready... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Award for Oral Nicotine Compound Patent
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Granted Important New Oral Nicotine Patent
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Studies Advance Lexaria Bioscience’s (NASDAQ: LEXX) Tech for Improving Pharmaceutical Drugs
Via Investor Brand Network
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster Delivery of Sildenafil
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Optimistic of Positive Study Results
Via Investor Brand Network
As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’
Via Investor Brand Network
Lexaria (NASDAQ: LEXX) Optimistic About Expanded DehydraTECH Investigations
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
Via Investor Brand Network
Lexaria (NASDAQ: LEXX) World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology
Via Investor Brand Network
Following Sildenafil Study, Lexaria (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022
Via Investor Brand Network
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated as Treatment for Multiple Conditions
Via Investor Brand Network
< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback